concurrent track: disease modeling
Examining advances in in vivo, in vitro, and in silico disease models to enable drug screening, toxicity assessment, and therapeutic development.
Organized by:
Shuibing Chen, PhD, Weill Cornell Medical College, USA
Hongkui Deng, PhD, Peking University, China
*Additional invited and abstract-selected speakers to be determined. Session descriptions and titles may change slightly.
aging models and age-related diseases
Li Gan, PhD, Weill Cornell Medical College, USA
-
This session explores the biological mechanisms of aging and highlights opportunities for intervention in age-related diseases such as Alzheimer’s and metabolic disorders.
precision medicine and drug evaluation
Daniela Cornacchia, PhD, AstraZeneca, Sweden
Hongjun Song, PhD, University of Pennsylvania, USA
-
This session focuses on the application of stem cell-based models in drug development and precision medicine, including toxicity testing.
advanced organoid models
Sasha Mendjan, PhD, Institute of Molecular Biotechnology, IMBA, Austria
Samira Musah, PhD, Duke University, USA
-
This session features organoid models that incorporate vascular, immune, and microtissue components to improve physiological relevance in disease modeling.
new approach methodologies
-
This session showcases New Approach Methodologies (NAMs) including in vitro and in silico techniques that advance research and accelerate translation. It also features a regulatory perspective on the role of NAMs’ in drug development and safety assessment.